Dutch Multiple sclerosis study (DMSS)
Completed
- Conditions
- Multiple sclerosis
- Registration Number
- NL-OMON22564
- Lead Sponsor
- ationaal MS Fonds Industrieweg 130C 3044 AT Rotterdam 010 – 591 98 39 info@nationaalmsfonds.nl Curavista bv Markt 9 4931 BR Geertruidenberg Tel: 0162 520 964 info@curavista.nl MS4 Research Institute Dr. Peter Joseph (Sjef) Jongen Ubbergseweg 34 6522 KJ Nijmegen The Netherlands
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 500
Inclusion Criteria
1) Diagnosis of MS or Clinically Isolated Syndrome (CIS)
2) Willing and able to comply with the study protocol
3) Having access to the internet
4) Have given informed consent
Exclusion Criteria
Not defined
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary study outcomes are disabilities (MSIP-Disability) and disability perceptions (MSIP-Disability perception)
- Secondary Outcome Measures
Name Time Method Disabilities as reported by an MS-specialized nurse (EDSS), health-related quality of life (MSQoL-54), and disease-modifying treatment utilization and persistence are the secondary outcomes of the study. Due to miscommunication, the two outcome measures; the Modified Fatigue Impact Scale-5 items (MFIS-5) and the Leeds Multiple Sclerosis Quality of Life (LMSQoL) reported in the initial study protocol were not included in the current study.